Patents by Inventor Hermann Gram
Hermann Gram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083997Abstract: This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.Type: ApplicationFiled: February 28, 2023Publication date: March 14, 2024Inventors: Hermann GRAM, Thomas JUNG, Philip LOWE, Trevor MUNDEL, Timothy WRIGHT
-
Publication number: 20230235038Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: July 7, 2022Publication date: July 27, 2023Inventors: Franco E. Di Padova, Hermann GRAM, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20210179705Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: February 26, 2021Publication date: June 17, 2021Inventors: Hermann GRAM, Thomas JUNG
-
Publication number: 20210147533Abstract: This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.Type: ApplicationFiled: June 19, 2020Publication date: May 20, 2021Inventors: Philip LOWE, Hermann GRAM, Thomas JUNG, Timothy WRIGHT, Trevor MUNDEL
-
Patent number: 10968272Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: September 13, 2018Date of Patent: April 6, 2021Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20190270804Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: May 15, 2019Publication date: September 5, 2019Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 10344084Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 11, 2017Date of Patent: July 9, 2019Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20190002554Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: September 13, 2018Publication date: January 3, 2019Inventors: Hermann Gram, Thomas Jung
-
Patent number: 10106604Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1 beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: November 23, 2016Date of Patent: October 23, 2018Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20180201674Abstract: This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.Type: ApplicationFiled: March 12, 2018Publication date: July 19, 2018Inventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Publication number: 20170355762Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 11, 2017Publication date: December 14, 2017Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 9765140Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2015Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20170218063Abstract: This invention relates to methods employing IL-1?-Ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: April 11, 2017Publication date: August 3, 2017Inventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Patent number: 9649377Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds such as IL-1? antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.Type: GrantFiled: July 28, 2015Date of Patent: May 16, 2017Assignee: Novartis AGInventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Publication number: 20170073411Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1 beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: November 23, 2016Publication date: March 16, 2017Inventors: Hermann Gram, Thomas Jung
-
Patent number: 9534047Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: September 22, 2015Date of Patent: January 3, 2017Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20160002328Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: September 22, 2015Publication date: January 7, 2016Applicant: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20150322148Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: July 28, 2015Publication date: November 12, 2015Applicant: Novartis AGInventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Patent number: 9168298Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand—IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: July 31, 2013Date of Patent: October 27, 2015Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20150152178Abstract: An IL-17 binding molecule, in particular .an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2015Publication date: June 4, 2015Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg